Approximately 15% of individuals suspected by their physician to have HHT have no mutation in ENG, ACVRL1, or SMAD4. Determining the genetic basis of HHT manifestations in patients who do not have a mutation in one these three genes has remained a great challenge for nearly a decade. This evidence concerns the gene SMAD4 and hereditary hemorrhagic telangiectasia.